p.7 抽出テキスト

CCU Coronary care unit CDK Cyclin-dependent kinase CHA2DS2-VASc Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points)—Vascular disease, Age 65–74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR Cardiac magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real-life patients—Cancer Associated Thrombosis CPET Cardiopulmonary exercise testing CrCl Creatinine clearance CRF Cardiorespiratory fitness CRS Cytokine release syndrome CS Cancer survivors CT Computed tomography CTLA-4 Cytotoxic T lymphocyte-associated antigen-4 cTn Cardiac troponin CTRCD Cancer therapy-related cardiac dysfunction CTR-CVT Cancer therapy-related cardiovascular toxicity CV Cardiovascular CVD Cardiovascular disease CVRF Cardiovascular risk factors DAPT Dual antiplatelet therapy DASISION DASatinib vs. Imatinib Study In treatment-Naïve chronic myeloid leukaemia patients DL Dyslipidaemia DM Diabetes mellitus DNR Do not resuscitate DVT Deep vein thrombosis E Mitral inflow early diastolic velocity obtained by pulsed wave e′ Early diastolic velocity of the mitral annulus obtained by tissue Doppler imaging EACTS European Association for Cardio-Thoracic Surgery EBC Early breast cancer ECG Electrocardiogram Echo Echocardiography ECV Extracellular volume fraction eGFR Estimated glomerular filtration rate EGFR Epidermal growth factor receptor EMA European Medicines Agency EMB Endomyocardial biopsy ENGAGE AF-TIMI 48 Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation- Thrombolysis in Myocardial Infarction 48 ENOXACAN Enoxaparin and Cancer EoL End of life ERS European Respiratory Society ESC European Society of Cardiology ESC-CCO European Society of Cardiology Council of Cardio-Oncology ESH European Society of Hypertension EuroSCORE European System for Cardiac Operative Risk Evaluation FAC Fractional area change FDA Food and Drug Administration FLT3 FMS-like tyrosine kinase 3 FWLS Free wall longitudinal strain GI Gastrointestinal GLS Global longitudinal strain GnRH Gonadotropin-releasing hormone GU Genitourinary GVHD Graft vs. host disease Gy Gray HAS-BLED Hypertension, Abnormal renal and liver function, Stroke, Bleeding Labile international normalized ratio, Elderly, Drugs or alcohol HbA1c Glycated haemoglobin HDU High-dependency unit HER2 Human epidermal receptor 2 HF Heart failure HFA Heart Failure Association HFmrEF Heart failure with mildly reduced ejection fraction HFpEF Heart failure with preserved ejection fraction HFrEF Heart failure with reduced ejection fraction HG Hyperglycaemia HIIT High-intensity interval training HSCT Haematopoietic stem cell transplantation hs-cTn High-sensitivity cardiac troponin HTN Hypertension ICD Implantable cardioverter defibrillator ICI Immune checkpoint inhibitors ICOS International Cardio-Oncology Society ICU Intensive care unit IHD Ischaemic heart disease IMiD Immunomodulatory drugs i.v. Intravenous IVC Inferior vena cava IVS Intraventricular septum LA Left atrial LAA Left atrial appendage LGE Late gadolinium enhancement LIMA Left internal mammary artery LMWH Low-molecular-weight heparins LQTS Long QT syndrome LS Longitudinal strain LV Left ventricular LVD Left ventricular dysfunction LVEDD Left ventricular end diastolic diameter LVEF Left ventricular ejection fraction LVV Left ventricular volume M Months MACE Major adverse cardiovascular events MCS Mechanical circulatory support MDT Multidisciplinary team Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026